Leveraging a flexible and efficient Rapid Development Framework™ to accelerate development and manufacturing of cell and gene therapies

Webinar On Demand

The translation of cell and gene therapies (CGTs) from innovative research and development processes to standardized and robust manufacturing methods often presents significant challenges. To successfully commercialize these novel products, it is crucial to identify and mitigate potential risks early through consistent processes and robust, qualifiable assays. Although traditional platform processes for CGTs can accelerate production timelines, they often impose restrictive protocols that may limit users to suboptimal systems.

In response to these challenges, Thermo Fisher Scientific has developed the Rapid Development Framework^TM, designed to streamline the complexities of regenerative medicine and immunotherapy workflows. Leveraging over 20 years of advanced therapy industry experience, this framework for processes and analytics can accelerate development and manufacturing timelines while remaining adaptable to the unique needs of each product. Our recent webinar covered these topics and more, specifically discussing the following key takeaways:

Examples of the Rapid Development Framework^TM for viral vector, CAR-T, and iPSC workflows, along with associated analytics
Additional pathways to accelerate drug development and manufacturing timelines leveraging CDMO capabilities
How this approach promotes consistency, reduces failure risks, and enhances product quality and patient safety
Practical examples of the Rapid Development Framework^TM in action, highlighting associated time and cost savings

Ready to discuss your project?

Connect with us

Leveraging a flexible and efficient Rapid Development Framework™ to accelerate development and manufacturing of cell and gene therapies

Webinar On Demand

<< Return to Library

Complete this short form to access the document.